Key result
The use of abatacept and mycophenolate mofetil led to the resolution of steroid-resistant immune checkpoint inhibitor-related myocarditis and myositis in a 57-year-old male.
Why the study?
ICI-related myocarditis is potentially fatal, and corticoid-resistant myocarditis induced by ICI poses an important therapeutic challenge.
Does the addition of abatacept and mycophenolate mofetil improve outcomes in patients with steroid-refractory ICI-related myocarditis and myositis?
Case Report (n=1)
Does the addition of abatacept and mycophenolate mofetil improve outcomes in patients with steroid-refractory ICI-related myocarditis and myositis?
Abatacept and mycophenolate mofetil may be effective supplementary immunosuppressive agents for the treatment of steroid-refractory ICI-related myocarditis and myositis.
No takes yet. Share an insight, caveat, or question.
Abatacept plus MMF may be considered in steroid-refractory ICI-myocarditis; leaves open need for prospective confirmation.
Jespersen et al. (2021) conducted a case report in Steroid-refractory immune checkpoint inhibitor-related myocarditis and myositis (n=1). Abatacept and mycophenolate mofetil was evaluated on Resolution of steroid-resistant ICI-related myocarditis and myositis. The use of abatacept and mycophenolate mofetil led to the resolution of steroid-resistant immune checkpoint inhibitor-related myocarditis and myositis in a 57-year-old male.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: